# BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

> **NCT03976973** · PHASE2 · UNKNOWN · sponsor: **Mucpharm Pty Ltd** · enrollment: 62 (estimated)

## Conditions studied

- Pseudomyxoma Peritonei
- Peritoneal Cancer
- Mucinous Adenocarcinoma
- Mucinous Tumor

## Interventions

- **DRUG:** Bromelain
- **DRUG:** Acetylcysteine
- **PROCEDURE:** Interventional radiology insertion of drain

## Key facts

- **NCT ID:** NCT03976973
- **Lead sponsor:** Mucpharm Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05
- **Primary completion:** 2023-11
- **Final completion:** 2024-02
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2022-03-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03976973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03976973, "BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03976973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*